Free Trial
→ Trump Orders 'National Digital Asset Stockpile' (From Crypto 101 Media) (Ad) Buy SNYNF Stock  Free SNYNF Stock Alerts

Sanofi (SNYNF) Financials

Sanofi logo
$102.86 -3.59 (-3.37%)
As of 02:11 PM Eastern
Compare
Annual Income Statements for Sanofi

Annual Income Statements for Sanofi

This table shows Sanofi's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 4,658 4,954 10,110 -32,165 8,019 15,018 7,043 8,955 5,973 5,755
Consolidated Net Income / (Loss)		 4,768 5,050 10,255 5,047 3,125 15,062 7,107 9,076 6,013 5,815
Net Income / (Loss) Continuing Operations		 4,902 4,719 4,678 5,062 3,239 15,062 7,107 8,647 5,639 5,749
Total Pre-Tax Income 		5,697 5,970 6,644 5,042 7,720 16,831 8,826 10,631 6,915 6,933
Total Operating Income		 6,111 7,013 7,163 5,352 3,424 7,597 8,791 10,535 6,589 6,982
Total Gross Profit		 26,014 25,243 29,560 27,745 28,788 30,797 30,468 30,681 32,069 32,172
Total Revenue		 37,878 36,500 43,510 0.00 42,232 46,502 44,338 43,392 46,038 45,840
Operating Revenue		 37,008 35,567 42,130 - 40,543 44,879 42,738 40,279 41,833 42,523
Other Revenue		 870 933 1,380 - 1,689 1,622 1,600 3,113 4,205 3,317
Total Cost of Revenue		 11,864 11,257 13,950 13,087 13,444 17,056 16,330 15,870 19,208 19,315
Operating Cost of Revenue		 11,864 11,257 13,950 13,087 13,444 17,056 16,330 15,870 19,208 19,315
Total Operating Expenses		 19,903 18,230 22,397 18,029 20,733 21,848 19,218 16,986 20,241 19,544
Selling, General & Admin Expense		 10,194 9,971 12,099 11,284 11,092 11,472 10,814 9,349 9,882 9,505
Research & Development Expense		 5,522 5,441 6,573 6,746 6,756 6,755 6,442 6,955 7,198 7,654
Amortization Expense		 2,322 1,780 2,242 - 2,408 2,054 1,788 1,930 2,114 1,810
Other Operating Expenses / (Income)		 168 134 -4.80 - 476 - -972 -1,941 -1,083 -1,127
Impairment Charge		 833 202 352 - - 403 217 -459 991 257
Restructuring Charge		 864 925 878 - - 1,330 928 1,152 1,139 1,445
Total Other Income / (Expense), net		 -414 -1,043 -519 -498 -336 9,234 35 95 326 -49
Interest & Investment Income		 193 72 177 - 158 65 45 219 646 537
Other Income / (Expense), net		 -607 -1,114 -696 - -494 9,169 -10 -124 -320 -586
Income Tax Expense		 770 1,394 2,069 551 136 2,207 1,763 2,042 1,125 1,246
Other Gains / (Losses), net		 -24 143 102 - 286 439 44 59 -150 62
Other Adjustments to Consolidated Net Income / (Loss)		 -135 330 5,577 - - - - 429 374 66
Net Income / (Loss) Attributable to Noncontrolling Interest		 110 -96 -145 - -35 -44 -63 -121 -40 -60
Basic Earnings per Share		 $3.56 $3.66 $8.05 - - $9.81 - $7.16 $4.77 $4.60
Weighted Average Basic Shares Outstanding		 1.42B 1.29B 1.26B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.26B
Diluted Earnings per Share		 $3.53 $3.63 $7.98 - - $9.76 - $7.12 $4.76 $4.59
Weighted Average Diluted Shares Outstanding		 1.43B 1.30B 1.27B 1.25B 1.26B 1.26B 1.26B 1.26B 1.26B 1.26B
Weighted Average Basic & Diluted Shares Outstanding		 - - 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B

Quarterly Income Statements for Sanofi

No quarterly income statements for Sanofi are available.

Annual Cash Flow Statements for Sanofi

This table details how cash moves in and out of Sanofi's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 1,963 8,417 -5,760 3,880 2,808 -5,880 -4,320 2,822 -6,308 -3,522
Net Cash From Operating Activities		 9,007 3,396 -6,439 6,349 8,658 -10,153 11,909 11,261 -753 -3,923
Net Cash From Continuing Operating Activities		 -819 3,396 -6,439 7,804 7,023 -10,153 8,053 10,311 -753 -3,923
Net Income / (Loss) Continuing Operations		 4,523 -330 -5,577 4,913 2,977 0.00 7,043 8,955 0.00 66
Consolidated Net Income / (Loss)		 4,658 - - 4,928 3,091 - 7,043 8,955 - 66
Depreciation Expense		 -4,646 3,473 - - - - - - - 3,712
Non-Cash Adjustments To Reconcile Net Income		 -1,843 254 115 1,740 2,724 -9,720 -543 -426 494 -7,517
Changes in Operating Assets and Liabilities, net		 1,146 - -977 1,151 1,322 -432 1,553 -1,236 -1,248 -184
Net Cash From Investing Activities		 -3,272 0.00 643 14,725 1,328 4,559 -8,260 -2,220 -5,274 1,512
Net Cash From Continuing Investing Activities		 -3,272 0.00 643 -12,239 826 4,559 -8,183 -2,265 -5,274 1,512
Sale of Property, Plant & Equipment		 229 - 643 2,476 1,374 1,121 765 1,434 893 1,512
Net Cash From Financing Activities		 -3,888 5,021 36 4,503 4,706 -286 -7,986 -6,227 -280 -925
Net Cash From Continuing Financing Activities		 -3,888 5,021 36 4,975 -4,533 -286 -7,517 -6,212 -280 -925
Repayment of Debt		 -985 - 0.00 -901 -2,619 -286 -2,705 -3,207 -280 -925
Effect of Exchange Rate Changes		 -252 - - 1.14 10 - 17 - - -186

Quarterly Cash Flow Statements for Sanofi

No quarterly cash flow statements for Sanofi are available.

Annual Balance Sheets for Sanofi

This table presents Sanofi's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 111,176 110,122 119,900 127,508 126,400 139,767 136,090 135,567 139,894 137,459
Total Current Assets		 27,085 28,079 31,658 28,131 32,109 41,172 34,592 36,401 33,911 30,120
Cash & Equivalents		 9,940 10,807 12,391 7,926 10,580 16,999 11,429 13,625 9,635 7,702
Accounts Receivable		 8,025 7,691 8,668 8,309 8,907 9,151 8,565 9,012 9,329 7,946
Inventories, net		 7,080 7,255 8,190 8,558 8,971 10,203 9,864 9,585 10,693 9,762
Current Deferred & Refundable Income Taxes		 - - - 1,023 907 1,476 693 400 433 749
Other Current Assets		 2,041 2,326 2,408 2,315 2,744 3,344 4,042 3,779 3,822 3,960
Plant, Property, & Equipment, net		 10,804 10,540 11,507 11,046 10,905 11,440 11,350 10,558 11,239 10,445
Plant, Property & Equipment, gross		 10,804 10,540 11,507 11,046 10,905 11,440 11,350 10,558 11,239 10,445
Total Noncurrent Assets		 73,287 71,503 76,736 88,075 82,837 87,155 90,148 88,608 94,745 96,894
Long-Term Investments		 2,908 3,042 3,420 3,894 4,030 246 283 724 469 327
Goodwill		 42,980 42,382 48,367 50,627 49,962 54,195 54,390 53,374 54,651 44,907
Intangible Assets		 13,067 11,445 15,712 25,052 18,527 22,405 24,228 23,150 26,902 23,423
Noncurrent Deferred & Refundable Income Taxes		 5,122 4,913 5,155 5,280 6,050 5,404 5,402 6,015 7,318 8,826
Other Noncurrent Operating Assets		 9,211 9,722 4,082 3,222 4,268 4,905 5,845 5,344 5,406 19,410
Total Liabilities & Shareholders' Equity		 111,176 110,122 119,900 127,508 126,400 139,767 136,090 135,567 139,894 137,459
Total Liabilities		 64,850 48,142 48,708 38,326 37,644 53,562 50,354 48,397 49,250 48,489
Total Current Liabilities		 18,140 17,298 18,575 9,232 11,370 23,513 24,102 25,647 26,778 30,186
Short-Term Debt		 3,733 1,856 1,532 3,013 5,111 3,380 3,603 4,465 2,262 4,357
Accounts Payable		 4,147 4,520 5,565 5,769 5,963 6,468 6,995 7,289 8,106 7,816
Current Deferred & Payable Income Tax Liabilities		 - - - 449 290 738 350 614 660 721
Other Current Liabilities		 10,259 10,922 11,478 - - 12,927 13,155 13,269 15,735 15,086
Total Noncurrent Liabilities		 46,711 30,844 31,366 40,054 37,049 38,946 33,859 29,522 30,867 26,684
Long-Term Debt		 14,253 17,689 17,209 25,187 22,592 24,121 19,380 15,894 15,871 12,205
Capital Lease Obligations		 - - 0.00 0.00 1,108 1,137 2,081 2,037 1,941 1,703
Noncurrent Deferred & Payable Income Tax Liabilities		 3,146 2,411 1,928 3,907 2,574 4,279 4,138 4,087 4,092 3,807
Other Noncurrent Operating Liabilities		 9,963 9,293 10,996 - - 473 653 721 554 589
Other Noncurrent Nonoperating Liabilities		 1,068 1,257 0.00 - - 39 0.00 11 14 2,206
Total Equity & Noncontrolling Interests		 127,855 62,352 71,395 67,566 66,471 77,447 78,525 80,791 82,596 80,952
Total Preferred & Common Equity		 126,321 60,724 69,959 67,384 66,276 77,269 78,129 80,398 82,249 80,590
Total Common Equity		 126,321 60,545 69,756 0.00 0.00 77,091 77,733 80,004 81,903 80,227
Common Stock		 63,073 60,545 69,756 - - 77,091 77,733 80,004 81,903 80,227
Noncontrolling Interest		 1,534 1,628 1,435 182 195 178 396 394 346 362

Quarterly Balance Sheets for Sanofi

This table presents Sanofi's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q4 2023 Q4 2024
Total Assets		 135,567 139,894 137,459
Total Current Assets		 36,401 33,911 30,120
Cash & Equivalents		 13,625 9,635 7,702
Accounts Receivable		 9,012 9,329 7,946
Inventories, net		 9,585 10,693 9,762
Current Deferred & Refundable Income Taxes		 400 433 749
Other Current Assets		 3,779 3,822 3,960
Plant, Property, & Equipment, net		 10,558 11,239 10,445
Plant, Property & Equipment, gross		 10,558 11,239 10,445
Total Noncurrent Assets		 88,608 94,745 96,894
Long-Term Investments		 724 469 327
Goodwill		 53,374 54,651 44,907
Intangible Assets		 23,150 26,902 23,423
Noncurrent Deferred & Refundable Income Taxes		 6,015 7,318 8,826
Other Noncurrent Operating Assets		 5,344 5,406 19,410
Total Liabilities & Shareholders' Equity		 135,567 139,894 137,459
Total Liabilities		 48,397 49,250 48,489
Total Current Liabilities		 25,647 26,778 30,186
Short-Term Debt		 4,465 2,262 4,357
Accounts Payable		 7,289 8,106 7,816
Current Deferred & Payable Income Tax Liabilities		 614 660 721
Other Current Liabilities		 13,269 15,735 15,086
Total Noncurrent Liabilities		 29,522 30,867 26,684
Long-Term Debt		 15,894 15,871 12,205
Capital Lease Obligations		 2,037 1,941 1,703
Noncurrent Deferred & Payable Income Tax Liabilities		 4,087 4,092 3,807
Other Noncurrent Operating Liabilities		 721 554 589
Other Noncurrent Nonoperating Liabilities		 11 14 2,206
Total Equity & Noncontrolling Interests		 80,791 82,596 80,952
Total Preferred & Common Equity		 80,398 82,249 80,590
Total Common Equity		 80,004 81,903 80,227
Common Stock		 80,004 81,903 80,227
Noncontrolling Interest		 394 346 362

Annual Metrics and Ratios for Sanofi

This table displays calculated financial ratios and metrics derived from Sanofi's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -3.64% 19.21% -100.00% 0.00% 10.11% -4.65% -2.13% 6.10% -0.43%
EBITDA Growth		 0.00% 993.13% -7.07% -38.55% -0.25% 252.53% -43.84% 16.77% -32.07% 20.58%
EBIT Growth		 0.00% 7.18% 9.65% -17.25% -45.25% 472.19% -47.63% 18.57% -39.79% 2.03%
NOPAT Growth		 0.00% 1.72% -8.23% -3.36% -29.44% 96.23% 6.57% 21.00% -35.19% 3.81%
Net Income Growth		 0.00% 5.91% 103.09% -50.78% -38.08% 381.92% -52.82% 27.72% -33.75% -3.29%
EPS Growth		 0.00% 2.80% 119.73% 0.00% 0.00% 0.00% 0.00% 0.00% -33.24% -3.60%
Operating Cash Flow Growth		 0.00% -62.30% -289.60% 198.60% 36.38% -217.26% 217.30% -5.44% -106.69% -420.76%
Free Cash Flow Firm Growth		 0.00% 0.00% 99.44% -41,940.79% 123.68% 81.90% -50.92% 121.34% -99.09% 4,312.95%
Invested Capital Growth		 0.00% 31.58% 7.23% 42.07% -2.75% -4.66% 1.49% -3.88% 5.67% 0.76%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 68.68% 69.16% 67.94% 0.00% 68.17% 66.23% 68.72% 70.71% 69.66% 70.18%
EBITDA Margin		 2.26% 25.67% 20.02% 0.00% 12.64% 40.47% 23.84% 28.44% 18.21% 22.05%
Operating Margin		 16.13% 19.21% 16.46% 0.00% 8.11% 16.34% 19.83% 24.28% 14.31% 15.23%
EBIT Margin		 14.53% 16.16% 14.86% 0.00% 6.94% 36.06% 19.80% 23.99% 13.62% 13.95%
Profit (Net Income) Margin		 12.59% 13.83% 23.57% 0.00% 7.40% 32.39% 16.03% 20.92% 13.06% 12.69%
Tax Burden Percent		 83.69% 84.58% 154.35% 100.11% 40.49% 89.49% 80.52% 85.38% 86.96% 83.88%
Interest Burden Percent		 103.51% 101.21% 102.73% 94.20% 263.46% 100.39% 100.52% 102.11% 110.31% 108.40%
Effective Tax Rate		 13.52% 23.35% 31.13% 10.92% 1.76% 13.12% 19.98% 19.21% 16.27% 17.98%
Return on Invested Capital (ROIC)		 10.06% 8.84% 6.89% 0.00% 3.24% 6.60% 7.15% 8.76% 5.63% 5.67%
ROIC Less NNEP Spread (ROIC-NNEP)		 10.75% 9.79% 118.92% 0.00% 2.59% 36.75% 7.51% 11.99% 8.69% 6.13%
Return on Net Nonoperating Assets (RNNOA)		 -6.33% -3.53% 8.45% 0.00% 1.42% 14.33% 1.96% 2.63% 1.73% 1.44%
Return on Equity (ROE)		 3.73% 5.31% 15.34% 7.26% 4.66% 20.93% 9.11% 11.39% 7.36% 7.11%
Cash Return on Invested Capital (CROIC)		 0.00% -18.44% -0.09% -29.45% 6.02% 11.38% 5.68% 12.72% 0.11% 4.91%
Operating Return on Assets (OROA)		 4.95% 5.33% 5.62% 0.00% 2.31% 12.60% 6.37% 7.67% 4.55% 4.61%
Return on Assets (ROA)		 4.29% 4.56% 8.92% 0.00% 2.46% 11.32% 5.15% 6.68% 4.37% 4.19%
Return on Common Equity (ROCE)		 3.68% 5.22% 14.94% 3.65% 0.00% 11.21% 9.05% 11.28% 7.29% 7.05%
Return on Equity Simple (ROE_SIMPLE)		 3.77% 8.32% 14.66% 7.49% 4.72% 19.49% 9.10% 11.29% 7.31% 7.22%
Net Operating Profit after Tax (NOPAT)		 5,284 5,375 4,933 4,767 3,364 6,601 7,034 8,511 5,517 5,727
NOPAT Margin		 13.95% 14.73% 11.34% 0.00% 7.97% 14.19% 15.87% 19.62% 11.98% 12.49%
Net Nonoperating Expense Percent (NNEP)		 -0.69% -0.95% -112.04% -1.38% 0.65% -30.15% -0.35% -3.23% -3.06% -0.46%
Return On Investment Capital (ROIC_SIMPLE)		 3.62% 6.56% 5.47% 4.98% 3.53% 6.22% 6.79% 8.25% 5.37% 5.77%
Cost of Revenue to Revenue		 31.32% 30.84% 32.06% 0.00% 31.83% 36.68% 36.83% 36.57% 41.72% 42.14%
SG&A Expenses to Revenue		 26.91% 27.32% 27.81% 0.00% 26.27% 24.67% 24.39% 21.55% 21.46% 20.74%
R&D to Revenue		 14.58% 14.91% 15.11% 0.00% 16.00% 14.53% 14.53% 16.03% 15.64% 16.70%
Operating Expenses to Revenue		 52.55% 49.95% 51.48% 0.00% 49.09% 46.98% 43.34% 39.15% 43.97% 42.63%
Earnings before Interest and Taxes (EBIT)		 5,503 5,899 6,468 5,352 2,930 16,767 8,781 10,411 6,269 6,396
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 857 9,371 8,709 5,352 5,339 18,820 10,569 12,341 8,383 10,108
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.68 0.72 0.71 0.73 0.76
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 106.80 0.00 16.26 171.54 5.13
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 1.23 1.13 1.26 1.30 1.31 1.33
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 6.46 3.48 7.93 6.32 10.07 10.60
Dividend Yield		 5.36% 5.60% 5.03% 5.18% 4.14% 4.07% 4.32% 0.00% 3.98% 8.16%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 15.47% 28.71% 12.61% 15.83% 9.93% 9.43%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.57 0.65 0.65 0.70 0.68 0.70 0.71
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 1.57 1.37 1.57 1.50 1.53 1.56
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 11.19 12.40 3.39 6.59 5.27 8.41 7.08
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 11.19 22.60 3.81 7.93 6.25 11.24 11.19
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 12.56 19.69 9.68 9.90 7.64 12.77 12.50
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 9.43 7.65 0.00 5.85 5.77 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 10.59 5.62 12.47 5.26 627.07 14.44
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.14 0.31 0.26 0.42 0.43 0.37 0.32 0.28 0.24 0.23
Long-Term Debt to Equity		 0.11 0.28 0.24 0.37 0.36 0.33 0.27 0.22 0.22 0.17
Financial Leverage		 -0.59 -0.36 0.07 0.29 0.55 0.39 0.26 0.22 0.20 0.24
Leverage Ratio		 0.87 1.16 1.72 1.78 1.89 1.85 1.77 1.71 1.69 1.70
Compound Leverage Factor		 0.90 1.18 1.77 1.68 4.99 1.86 1.78 1.74 1.86 1.84
Debt to Total Capital		 12.33% 23.87% 20.79% 29.45% 30.24% 27.00% 24.20% 21.70% 19.55% 18.41%
Short-Term Debt to Total Capital		 2.56% 2.27% 1.70% 3.15% 5.36% 3.19% 3.48% 4.33% 2.20% 4.39%
Long-Term Debt to Total Capital		 9.77% 21.60% 19.09% 26.30% 24.87% 23.81% 20.72% 17.38% 17.35% 14.02%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 1.05% 1.99% 1.59% 0.19% 0.20% 0.17% 0.38% 0.38% 0.34% 0.37%
Common Equity to Total Capital		 86.62% 73.93% 77.39% 0.00% 0.00% 72.67% 75.04% 77.53% 79.77% 80.86%
Debt to EBITDA		 20.98 2.09 2.15 5.27 5.40 1.52 2.37 1.81 2.39 1.81
Net Debt to EBITDA		 5.99 0.61 0.34 3.06 2.66 0.61 1.26 0.65 1.19 1.01
Long-Term Debt to EBITDA		 16.63 1.89 1.98 4.71 4.44 1.34 2.03 1.45 2.12 1.38
Debt to NOPAT		 3.40 3.64 3.80 5.92 8.56 4.34 3.56 2.63 3.64 3.19
Net Debt to NOPAT		 0.97 1.06 0.59 3.44 4.22 1.73 1.90 0.95 1.81 1.79
Long-Term Debt to NOPAT		 2.70 3.29 3.49 5.28 7.05 3.83 3.05 2.11 3.23 2.43
Altman Z-Score		 0.00 0.00 0.00 0.99 1.43 1.47 1.30 1.37 1.27 1.24
Noncontrolling Interest Sharing Ratio		 1.20% 1.76% 2.58% 49.80% 100.00% 46.43% 0.74% 0.99% 0.91% 0.87%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 1.49 1.62 1.70 3.05 2.82 1.75 1.44 1.42 1.27 1.00
Quick Ratio		 0.99 1.07 1.13 1.76 1.71 1.11 0.83 0.88 0.71 0.52
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -11,217 -63 -26,417 6,255 11,378 5,584 12,360 112 4,959
Operating Cash Flow to CapEx		 323.70% 0.00% 0.00% 0.00% 0.00% -713.39% 769.71% 1,379.55% -32.44% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -53.06 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 12.75 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 17.72 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.34 0.33 0.38 0.00 0.33 0.35 0.32 0.32 0.33 0.33
Accounts Receivable Turnover		 4.72 4.64 5.32 0.00 4.91 5.15 5.01 4.94 5.02 5.31
Inventory Turnover		 1.68 1.57 1.81 1.56 1.53 1.78 1.63 1.63 1.89 1.89
Fixed Asset Turnover		 3.51 3.42 3.95 0.00 3.85 4.16 3.89 3.96 4.22 4.23
Accounts Payable Turnover		 2.86 2.60 2.77 2.31 2.29 2.74 2.43 2.22 2.50 2.43
Days Sales Outstanding (DSO)		 77.33 78.58 68.62 0.00 74.40 70.87 72.92 73.93 72.70 68.78
Days Inventory Outstanding (DIO)		 217.82 232.38 202.05 233.54 237.96 205.16 224.26 223.65 192.67 193.27
Days Payable Outstanding (DPO)		 127.59 140.52 131.95 158.06 159.27 133.01 150.46 164.25 146.27 150.44
Cash Conversion Cycle (CCC)		 167.55 170.45 138.72 0.00 153.09 143.02 146.72 133.33 119.10 111.60
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 52,533 69,126 74,122 105,306 102,415 97,638 99,088 95,239 100,643 101,411
Invested Capital Turnover		 0.72 0.60 0.61 0.00 0.41 0.46 0.45 0.45 0.47 0.45
Increase / (Decrease) in Invested Capital		 0.00 16,593 4,996 31,185 -2,891 -4,777 1,450 -3,849 5,404 768
Enterprise Value (EV)		 0.00 0.00 0.00 59,898 66,223 63,888 69,612 65,022 70,468 71,599
Market Capitalization		 0.00 0.00 0.00 43,335 51,827 52,316 55,865 56,581 60,152 61,001
Book Value per Share		 $89.01 $47.06 $55.50 $0.00 $0.00 $61.48 $62.06 $63.91 $64.96 $63.43
Tangible Book Value per Share		 $49.51 $5.22 $4.52 ($60.35) ($54.99) $0.39 ($0.71) $2.78 $0.28 $9.41
Total Capital		 145,842 81,897 90,135 95,767 95,282 106,085 103,589 103,188 102,670 99,216
Total Debt		 17,987 19,545 18,741 28,201 28,811 28,638 25,064 22,396 20,074 18,264
Total Long-Term Debt		 14,253 17,689 17,209 25,187 23,700 25,258 21,461 17,931 17,812 13,908
Net Debt		 5,139 5,696 2,930 16,381 14,201 11,394 13,352 8,047 9,970 10,235
Capital Expenditures (CapEx)		 2,783 0.00 -643 -2,476 -1,374 1,423 1,547 816 2,322 -1,512
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2,739 1,829 2,224 13,987 15,271 4,040 2,664 1,594 -240 -3,411
Debt-free Net Working Capital (DFNWC)		 12,679 12,637 14,614 21,913 25,850 21,038 14,093 15,219 9,395 4,292
Net Working Capital (NWC)		 8,946 10,781 13,083 18,899 20,739 17,658 10,491 10,754 7,133 -65
Net Nonoperating Expense (NNE)		 517 326 -5,322 -280 238 -8,462 -72 -565 -497 -88
Net Nonoperating Obligations (NNO)		 -75,321 6,774 2,727 37,740 35,944 20,191 20,563 14,448 18,048 20,459
Total Depreciation and Amortization (D&A)		 -4,646 3,473 2,242 0.00 2,408 2,054 1,788 1,930 2,114 3,712
Debt-free, Cash-free Net Working Capital to Revenue		 7.23% 5.01% 5.11% 0.00% 36.16% 8.69% 6.01% 3.67% -0.52% -7.44%
Debt-free Net Working Capital to Revenue		 33.47% 34.62% 33.59% 0.00% 61.21% 45.24% 31.79% 35.07% 20.41% 9.36%
Net Working Capital to Revenue		 23.62% 29.54% 30.07% 0.00% 49.11% 37.97% 23.66% 24.78% 15.49% -0.14%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $8.06 $3.45 $2.51 $0.00 $0.00 $6.69 $0.00 $4.60
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 1.51B 1.25B 1.25B 1.25B 0.00 1.26B 1.26B 1.26B
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $8.00 $3.43 $2.50 $0.00 $0.00 $6.66 $0.00 $4.59
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 1.52B 1.26B 1.26B 1.25B 0.00 1.26B 1.26B 1.26B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 1.25B 1.25B 1.25B 1.25B 0.00 1.25B 1.25B 1.25B
Normalized Net Operating Profit after Tax (NOPAT)		 6,752 6,069 5,958 4,767 3,364 7,963 7,951 9,071 7,301 7,123
Normalized NOPAT Margin		 17.83% 16.63% 13.69% 0.00% 7.97% 17.12% 17.93% 20.91% 15.86% 15.54%
Pre Tax Income Margin		 15.04% 16.36% 15.27% 0.00% 18.28% 36.20% 19.91% 24.50% 15.02% 15.12%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 10.75 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 9.58 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 15.72 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 14.55 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 84.46% 0.00% 0.00% 85.87% 138.17% 0.00% 64.60% 50.27% 0.00% 0.00%
Augmented Payout Ratio		 125.11% 0.00% 0.00% 110.84% 138.74% 0.00% 70.68% 56.13% 0.00% 0.00%

Quarterly Metrics and Ratios for Sanofi

No quarterly metrics and ratios for Sanofi are available.

Frequently Asked Questions About Sanofi's Financials

When does Sanofi's fiscal year end?

According to the most recent income statement we have on file, Sanofi's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Sanofi's net income changed over the last 9 years?

Sanofi's net income appears to be on an upward trend, with a most recent value of $5.82 billion in 2024, rising from $4.77 billion in 2015. The previous period was $6.01 billion in 2023.

What is Sanofi's operating income?
Sanofi's total operating income in 2024 was $6.98 billion, based on the following breakdown:
  • Total Gross Profit: $32.17 billion
  • Total Operating Expenses: $19.54 billion
How has Sanofi revenue changed over the last 9 years?

Over the last 9 years, Sanofi's total revenue changed from $37.88 billion in 2015 to $45.84 billion in 2024, a change of 21.0%.

How much debt does Sanofi have?

Sanofi's total liabilities were at $48.49 billion at the end of 2024, a 1.5% decrease from 2023, and a 25.2% decrease since 2015.

How much cash does Sanofi have?

In the past 9 years, Sanofi's cash and equivalents has ranged from $7.70 billion in 2024 to $17.00 billion in 2020, and is currently $7.70 billion as of their latest financial filing in 2024.

How has Sanofi's book value per share changed over the last 9 years?

Over the last 9 years, Sanofi's book value per share changed from 89.01 in 2015 to 63.43 in 2024, a change of -28.7%.


Related Companies

This page (OTCMKTS:SNYNF) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners
Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...
Stansberry Research | Sponsored
"I'm risking my reputation on this"
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...
Crypto 101 Media | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Secret financial plot unfolding in Washington DC… [DEVELOPING]
What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...
Timothy Sykes | Sponsored
Trump purposefully forcing markets to crash…
Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...
Porter & Company | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored